Why Is Merck Stock Up Today?
A trial where Merck's own blockbuster was the comparator just beat it — and Merck co-owns the regimen that did.
- The Phase 3 INTerpath-001 trial showed intismeran autogene plus KEYTRUDA beat KEYTRUDA alone in 1,137 resected stage IIB-IV melanoma patients.
- KEYTRUDA monotherapy was the control arm; Merck co-owns the winning combination, so the franchise extends rather than erodes.
- Measured at the print, Merck moved +4.845% in 15 minutes — versus +2.033% for its own Q2 earnings and -0.293% for its own FDA filing acceptance.
13:40:34 ET
Reaction by asset (real prices)
| Asset | 2m before | At release | +1m | +15m | +1m % | +15m % | Vol vs normal |
|---|---|---|---|---|---|---|---|
| MRK | 136.22 | 136.22 | 137.31 | 142.82 | +0.80% | +4.85% | — |
Merck rose 10.97% to $150.89 after the Phase 3 INTerpath-001 trial it runs with Moderna showed that combining Moderna's individualized neoantigen therapy with Merck's KEYTRUDA beat KEYTRUDA on its own in resected melanoma. Measured at the instant the result crossed the tape, Merck went from $136.22 to $142.82 in 15 minutes — +4.845%.
The detail worth sitting with is what the control arm was. KEYTRUDA monotherapy is Merck's own product, and in this trial it was the thing to beat. It was beaten.
Why beating your own drug is good news here
An adjuvant trial asks whether treatment after surgery keeps the cancer from returning. The comparison was KEYTRUDA alone versus KEYTRUDA plus intismeran autogene, across 1,137 patients with completely resected stage IIB-IV melanoma, randomised 2:1.
Merck co-owns the winning arm, so the commercial read is straightforward: the standard of care in this setting moves from a Merck product to a Merck product plus something else, and Merck is on both sides of that transition. Every patient who receives the combination still receives KEYTRUDA.
The subtler read is that KEYTRUDA monotherapy has just been established as no longer the ceiling in adjuvant melanoma. The franchise's future in this indication now runs through technology Merck does not own outright — which is a different position from the one it was in yesterday, even though the immediate effect is additive.
What our measurements say about how Merck normally trades
We record the price of every instrument at the moment a headline crosses. Merck's own recent announcements moved it very little.
| Merck headline (measured, 15 min) | Move |
|---|---|
| Partner trial: intismeran plus KEYTRUDA beats KEYTRUDA alone | +4.845% |
| Its own Q2 earnings print | +2.033% |
| Its own Q2 revenue detail, same morning | -1.246% |
| Its own FDA acceptance of a supplemental filing | -0.293% |
| Its own KEYTRUDA combination approval (June) | -0.102% |
An FDA acceptance of one of its own supplemental filings measured -0.293%. Its own second-quarter earnings print measured +2.033%, and the revenue detail that followed minutes later -1.246%. A KEYTRUDA combination approval in June measured -0.102%.
Nothing Merck announced about itself over two months moved this stock more than about two percent in the quarter-hour that followed. A trial result announced by a partner, in one tumour type, moved it more than twice that — and the session carried it further still. For a company of Merck's size that ordering is unusual, and it says the market is repricing something structural rather than reacting to a single indication.
What is not yet known
No hazard ratios, p-values or percentage risk reductions were released. "Statistically significant and clinically meaningful" describes a category, not a magnitude, and the full data are reserved for an upcoming international medical meeting. Overall survival is still being followed, and no date was given for when a regulator might accept a filing.
The wider programme is 9 Phase 2 and Phase 3 trials across melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma. Every one of them pairs the same individualized therapy with KEYTRUDA, so Merck's exposure to this technology extends well beyond the indication that read out.
Common questions
Why is Merck stock up today?
The Phase 3 INTerpath-001 trial, run with Moderna, showed that Moderna's individualized neoantigen therapy combined with Merck's KEYTRUDA beat KEYTRUDA alone on recurrence-free and distant metastasis-free survival in resected melanoma. Measured from the moment the result crossed the tape, Merck moved from $136.22 to $142.82 over 15 minutes, +4.845%.
Is this good or bad for KEYTRUDA?
Both, and that is what makes it interesting. KEYTRUDA alone was the control arm and was beaten, so the trial establishes that monotherapy is no longer the best available option in this setting. Merck co-owns the regimen that beat it, so the franchise extends rather than erodes — but it now extends through a partner's technology.
What did the trial actually show?
In 1,137 patients with completely resected stage IIB-IV melanoma randomised 2:1, the combination met both endpoints at a pre-specified interim analysis. No hazard ratios or p-values were released, so the size of the benefit is not yet public, and overall survival is still being followed.
How does this compare with Merck's own recent news?
Measured over the past 60 days, Merck's own announcements barely moved it: its Q2 earnings print +2.033%, the revenue detail that followed -1.246%, an FDA acceptance of a supplemental filing -0.293%, and a KEYTRUDA combination approval in June -0.102%. This partner readout moved it +4.845% in a quarter of an hour.
Sources
-
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA Met Endpoints of RFS and DMFS in Melanoma
— Moderna
1,137 patients randomised 2:1 to intismeran autogene plus KEYTRUDA versus KEYTRUDA alone in resected stage IIB-IV melanoma; the combination met recurrence-free survival and distant metastasis-free survival at a pre-specified interim analysis, with the study continuing to follow overall survival; the INTerpath programme comprises nine Phase 2 and Phase 3 trials; the companies will present data at an international medical meeting and engage regulators on filing submissions; first positive Phase 3 for an individualized neoantigen therapy and for an mRNA-based cancer therapy.
-
Merck, Moderna claim 'promising' skin cancer vaccine results in key trial
— Medical Xpress
The companies did not provide specific details of the study results, disclosing no hazard ratios, p-values or percentage risk reductions, and did not say when the FDA might accept a filing.
Never miss the next market-moving story
Seven market specialists, with experience dating back to 2006, watch global markets and U.S. stocks of every size. Start Pro to get the full live feed, clear context, measured price moves, search, watchlists, and alerts.
Start Pro — $29 for 7 days Watch MRK live -- free